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A B S T R A C T
Background
Chronic obstructive pulmonary disease (COPD) (commonly referred to as chronic bronchitis and emphysema) is a chronic lung
condition characterised by the inflammation of airways and irreversible destruction of pulmonary tissue leading to progressively
worsening dyspnoea. It is a leading international cause of disability and death in adults. Evidence suggests that there is an increased
prevalence of anxiety disorders in people with COPD. The severity of anxiety has been shown to correlate with the severity of COPD,
however anxiety can occur with all stages of COPD severity. Coexisting anxiety and COPD contribute to poor health outcomes in
terms of exercise tolerance, quality of life and COPD exacerbations. The evidence for treatment of anxiety disorders in this population
is limited, with a paucity of evidence to support the efficacy of medication-only treatments. It is therefore important to evaluate
psychological therapies for the alleviation of these symptoms in people with COPD.
Objectives
To assess the effects of psychological therapies for the treatment of anxiety disorders in people with chronic obstructive pulmonary
disease.
Search methods
We searched the specialised registers of two Cochrane Review Groups: Cochrane Common Mental Disorders (CCMD) and Cochrane
Airways (CAG) (to 14 August 2015). The specialised registers include reports of relevant randomised controlled trials from The
Cochrane Library, MEDLINE, Embase, and PsycINFO. We carried out complementary searches on PsycINFO and CENTRAL to
ensure no studies had been missed. We applied no date or language restrictions.
Selection criteria
We considered all randomised controlled trials (RCTs), cluster-randomised trials and cross-over trials of psychological therapies for
people (aged over 40 years) with COPD and coexisting anxiety disorders (as confirmed by recognised diagnostic criteria or a validated
measurement scale), where this was compared with either no intervention or education only. We included studies in which the
psychological therapy was delivered in combination with another intervention (co-intervention) only if there was a comparison group
that received the co-intervention alone.
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Data collection and analysis
Two review authors independently screened citations to identify studies for inclusion and extracted data into a pilot-tested standardised
template. We resolved any conflicts that arose through discussion. We contacted authors of included studies to obtain missing or raw
data. We performed meta-analyses using the fixed-effect model and, if we found substantial heterogeneity, we reanalysed the data using
the random-effects model.
Main results
We identified three prospective RCTs for inclusion in this review (319 participants available to assess the primary outcome of anxiety).
The studies included people from the outpatient setting, with the majority of participants being male. All three studies assessed
psychological therapy (cognitive behavioural therapy) plus co-intervention versus co-intervention alone. We assessed the quality of
evidence contributing to all outcomes as low due to small sample sizes and substantial heterogeneity in the analyses. Two of the three
studies had prespecified protocols available for comparison between prespecified methodology and outcomes reported within the final
publications.
We observed some evidence of improvement in anxiety over 3 to 12 months, as measured by the Beck Anxiety Inventory (range from 0
to 63 points), with psychological therapies performing better than the co-intervention comparator arm (mean difference (MD) -4.41
points, 95% confidence interval (CI) -8.28 to -0.53; P = 0.03). There was however, substantial heterogeneity between the studies (I2
= 62%), which limited the ability to draw reliable conclusions. No adverse events were reported.
Authors’ conclusions
We found only low-quality evidence for the efficacy of psychological therapies among people with COPD with anxiety. Based on the
small number of included studies identified and the low quality of the evidence, it is difficult to draw any meaningful and reliable
conclusions. No adverse events or harms of psychotherapy intervention were reported.
A limitation of this review is that all three included studies recruited participants with both anxiety and depression, not just anxiety,
which may confound the results. We downgraded the quality of evidence in the ’Summary of findings’ table primarily due to the small
sample size of included trials. Larger RCTs evaluating psychological interventions with a minimum 12-month follow-up period are
needed to assess long-term efficacy.
P L A I N L A N G U A G E S U M M A R Y
Psychotherapy for treatment of anxiety in chronic obstructive pulmonary disease (chronic bronchitis and emphysema)
Why is this review important?
Chronic obstructive pulmonary disease (COPD) is commonly referred to as emphysema and chronic bronchitis. People with COPD
are more likely to have anxiety disorders compared with the general population. Symptoms of anxiety affect various aspects of daily
life, including quality of life and the ability to perform physical activities. Psychological therapies are used as part of clinical practice to
treat these symptoms, however, there is little evidence to support these techniques.
Who will be interested in this review?
Health professionals and people with emphysema and underlying anxiety and panic.
What questions does this review aim to answer?
What is the current evidence on psychological therapies for anxiety in people with COPD and coexisting anxiety?
Which studies were included in the review?
Randomised controlled trials (research trials inwhich participants are allocated according to a random sequence either to the intervention
to be tested or to a comparator intervention).
What does the evidence from the review tell us?
This systematic review found three studies with a total of 319 participants with COPD and coexisting anxiety. All three studies assessed
psychotherapy (CBT) with a co-intervention, versus the co-intervention alone. There was limited evidence showing some improvements
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in reduced levels of anxiety and improved quality of life in the psychotherapy group. It is important to note that the overall quality of
the evidence was low and hence further research is needed to increase our confidence in this effect. A limitation of this review is that
all three included studies recruited participants with both anxiety and depression, not just anxiety, which may confound the results.
What should happen next?
Further research is needed to establish whether this therapy will reduce hospital admissions and length of hospital stays, as this was not
assessed in the current evidence base. Larger studies of longer duration need to be conducted. There are at least two more clinical trials
currently ongoing for this question. Once they are published, the evidence from them could increase or decrease our confidence in the
findings of this review.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Psychological therapies for anxiety for people with COPD
Patient or population: people with COPD
Settings: hospital and home
Intervention: psychological therapies plus co-intervent ions for anxiety
Comparators: co-intervent ion alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Psychological thera-
pies for anxiety
Anxiety
Becks Anxiety Inven-
tory. Scale f rom: 0 to
63.
Follow-up: 3-12 months
The mean anxiety in the
control groups was
15.51
The mean anxiety in
the intervent ion groups
was
4.41 lower
(8.28 to 0.53 lower)
319
(3 studies)
⊕⊕©©
low1,2
Benef icial
f indings were observed
in favour of the psycho-
logical therapy group
(p= 0.03), with levels
of anxiety half that of
the control populat ion
by f inal follow-up (Gillis
1995)
Adverse events Study population Not est imable 0
(0)
See comment No studies reported on
adverse events
See comment See comment
Moderate
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Quality of life - physical
composite
SGRQ and SF36
Follow-up: 6-12 months
The mean quality of lif e
- physical composite in
the control groups was
45.08
The mean quality of lif e
- physical composite in
the intervent ion groups
was
0.40 standard devia-
tions lower
(0.88 lower to 0.08
higher)
289
(2 studies)
⊕⊕©©
low1,3
Two studies reported
on quality of lif e with
one study (Kunik 2008)
report ing both SF36
and CRQ. Meta-analysis
occurred only for SF36
composite scores with
SGRQ, as no totals were
available for CRQ. Sub-
group analyses sepa-
rat ing short-term (0 to
3 months; SMD -0.22,
95%CI -0.45 to 0.01; P =
0.06) and long-term fol-
low-up (6 to 12 months;
SMD -0.30, 95% CI -0.
53 to -0.06; P = 0.01)
resulted in better treat-
ment outcomes long-
term
Quality of life - emo-
tional composite
SGRQ and SF36
Follow-up: 6-12 months
The mean quality of lif e
- emotional composite
in the control groups
was
52.3
The mean quality of
lif e - emotional com-
posite in the interven-
t ion groups was
0.30 standard devia-
tions lower
(1.03 lower to 0.44
higher)
289
(2 studies)
⊕⊕©©
low1,3
Two studies reported
on quality of lif e with
one study (Kunik 2008)
report ing both SF36
and CRQ. We only meta-
analysed SF36 compos-
ite scores with SGRQ
as no totals were avail-
able for CRQ. Sub-
group analyses sepa-
rat ing short-term (0 to
3 months; (SMD 0.05,
95% CI -0.18 to 0.28)
and long-term follow-up
(6 to 12 months; (SMD
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-0.09, 95% CI -0.32 to
0.14) resulted in bet-
ter treatment outcomes
long-term
Exercise capacity
6MWD
Follow-up: 3-12 months
The mean exercise ca-
pacity in the control
groups was
839
The mean exercise ca-
pacity in the interven-
t ion groups was
2.78 lower
(58.49 lower to 52.94
higher)
268
(2 studies)
⊕⊕©©
low1,4
The Kunik 2008 study
which examined 6MWD
at 8 weeks (post-in-
tervent ion) and again
at 12 months’ follow-
up with a dif ference
in favour of the con-
trol arm at 12 months
(P = 0.05). However,
authors reported that
group means at begin-
ning of the follow-up pe-
riod were not equal (P
< 0.01), contribut ing to
the spurious f inding
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
6MWD: six m inute walking distance; CI: conf idence interval; CRQ: Chronic Respiratory Quest ionnaire; SF36: Short Form 36; SGRQ: Saint George’s Respiratory Quest ionnaire
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Substant ial heterogeneity as ident if ied via the I-squared stat ist ic and visual inspect ion of the data.
2Two of the three studies have sample sizes lower than the prespecif ied opt imal sample size, study part icipants were
predominant ly men across all three studies and most subjects had comorbid anxiety and depression, therefore imprecision
was downgraded by one point.
3Both studies had sample sizes lower than the prespecif ied opt imal sample size.
4Wide conf idence intervals around ef fect est imate.
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B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a chronic lung
condition characterised by the inflammation of airways and irre-
versible destruction of pulmonary tissue leading to progressively
worsening dyspnoea and is a leading international cause of disabil-
ity and death in adults (Kerstjens 2001). COPD is a preventable
and treatable disease with some significant extrapulmonary ef-
fects. Its pulmonary component is characterised by airflow lim-
itation that is not fully reversible (GOLD 2013). The diagno-
sis of COPD is based on the person’s history, evaluation of risk
factors and relevant investigations, including pulmonary function
testing and chest imaging. Spirometry will typically show a post
bronchodilator forced expiratory volume 1/forced vital capacity
(FEV1/FVC) less than 70% (Rabe 2007). Anxiety disorder is a
generalised term for a myriad of abnormal and pathological fear
and anxiety states, including generalised anxiety disorder (GAD),
panic disorder (PD), agoraphobia, neurocirculatory asthenia, ob-
sessive-compulsive disorder (OCD), and phobic disorders. GAD
is defined as excessive anxiety which lasts for at least six months.
Individuals must also experience three or more of the following
symptoms: difficulty in concentrating; fatigue after little exertion;
sleep disturbance; a sensation of being ’keyed up’ (nervous or anx-
ious); irritability or muscle tension, or both (Diagnostic and Sta-
tistical Manual (DSM) IV criteria) (APA 1994). Other anxiety
symptoms can include increased behavioural and psychological
symptoms of distress (Suh 2013) and fears (Breland 2015), which
is of particular importance as disease-specific fears can have an
impact on disability (Keil 2014).
Evidence suggests that there is an increased prevalence of anxiety
disorders in people with COPD (Maurer 2008). Moreover, the
severity of anxiety has been shown to correlate with the severity
of COPD and the presence of lower PaO (partial pressure of
oxygen in the blood, an indicator of severity of COPD)(Elassal
2014). Other studies suggest that anxiety can occur at any stage
of COPD (Kim 2000; Heslop-Marshall 2014. Studies have sug-
gested prevalence rates for anxiety disorders of 28%-36% in peo-
ple with COPD (Di Marco 2006; Yohannnes 2006). The lifetime
prevalence of GAD in particular amongst people with COPD is
estimated at between 10% and 15.8% (Brenes 2003). The preva-
lence of panic disorder in the COPD population is estimated to
be ten times higher than the general population (Smoller 1996;
Smoler 1999). Rates of anxiety symptoms in people with COPD
range from 13% to 51% and are higher than the rates in people
with heart failure, cancer, and other medical conditions (Brenes
2003). COPD is associated with a higher risk of anxiety, and co
morbid COPD and anxiety is related to poor health outcomes in
terms of exercise tolerance, quality of life, COPD exacerbations
(Eisner 2010), inappropriate use of medications and persistence
of smoking as a coping strategy for anxiety management (Royal
College of Physcians). Several risk factors have been identified that
contribute to anxiety amongst people with COPD, including be-
ing employed, less education, lack of contentment with family
support, living with family and friends, comorbid hypertension
and depression, and having 10 ormore exacerbations per year (Tan
2013). Indeed, co-morbid depression is known to be a strong pre-
dictor of anxiety (DiNicola 2013), which confounds anxiety symp-
toms making treatment more difficult (Atlantis 2013). By com-
promising health status, mood disorders lead to increased risk of
hospitalisation and re-hospitalisation (Gudmundsson 2005) and
hence also increase direct and indirect costs to the health system.
Various models could be considered to explain increased levels
of anxiety and panic in people with COPD (Ley 1985; Perna
2004). One model explains this relationship as catastrophic mis-
interpretations of ambiguous bodily sensations (such as shortness
of breath, rapid heart rate) which increase arousal, creating a pos-
itive feedback loop that results in a panic attack (Clark 1986).
A crucial difference between physically healthy people and those
with COPD is that in the latter, breathing, the most basic of all
physical functions necessary for life, is objectively threatened (as
measured by tests of lung function) and subjectively difficult. Dys-
pnoea (shortness of breath) can be an unpleasant and potentially
frightening experience at any time, and, as the key symptom of an
eventually fatal illness like COPD, it is an ambiguous sensation
open to catastrophic interpretation, leading to increased levels of
anxiety and panic in people with COPD (Livermore 2010b).
Description of the intervention
Management strategies for the treatment of anxiety disorders in
people with COPD include both pharmacological and non-phar-
macological interventions. Evidence that pharmacological ther-
apies (anti-anxiety or antidepressant medications, or both) pro-
vide statistically or clinically significant benefits for this group
of patients is limited (Usmani 2011). Psychological therapies in-
clude cognitive or behavioural therapies, or both, psychodynamic
psychotherapy, interpersonal psychotherapy, non-directive ther-
apy, support therapy and counselling (Rose 2002; Davison 2003).
Psychological therapies are intentional interpersonal relationships
used by trained psychotherapists to aid people with problems of
living, with an aim of increasing the individual’s well-being. Psy-
chological therapies may also be performed by practitioners with a
number of different qualifications, including psychologists, mar-
riage and family therapists, occupational therapists, licensed clin-
ical social workers, counsellors, psychiatric nurses, psychother-
apists, trained general nurses, psychoanalysts, and psychiatrists.
The mode of delivery for these therapies may comprise individ-
ual, group or family (including couple) therapy, performed by a
healthcare professional.
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How the intervention might work
Because COPD is an irreversible condition, treatment recommen-
dations are aimed at improving quality of life (Norweg 2005).
Current evidence examining quality of life suggests a reduction in
satisfaction above and beyond what should be expected by COPD
disease severity or co-morbid medical illnesses (Coventry 2007),
indicating that psychological status plays an intrinsic role in over-
all well-being. A recent study examining the impact of anxiety on
the lives of people with COPD found that they felt isolated and
would avoid social occasions and usual daily activities (Willgoss
2011). As a result, therapies targeting the reduction of psycholog-
ical stressors should be expected to improve quality of life (Ries
1995; Rose 2002; Baraniak 2011).
Psychological therapies are often based on the assumption that
psychological outcomes such as anxiety are linked with physical
manifestations of COPD, for example dyspnoea, which can pre-
cipitate episodes of anxiety (Wu 2004). It has been hypothesised
that a person’s fear and misinterpretation of bodily experiences
from dyspnoea and hyperventilation may cause a panic reaction
(Nutt 1999). Alternatively, underlying psychological distress can
contribute to an increased risk of symptom exacerbations, par-
ticularly those treated in the person’s own environment (Laurin
2011). As such, people with anxiety and panic disorders interpret
threats as more dangerous due to a higher awareness of cues such
as dyspnoea and tachycardia (Mikkelsen 2004).
A psychological therapy, cognitive-behaviour therapy (CBT), aims
to identify and correct dysfunctional emotions, behaviours and
cognitions through a goal-orientated, systematic procedure (Rose
2002; Kaplan 2009). In the case of people with COPD, CBTmay
be a means of managing concurrent anxiety and depression. While
not in itself improving an individual’s medical condition, CBT
may serve to increase perceived self-efficacy andmotivate people to
manage their physical condition, thereby improving quality of life
(Kunik 2001). Moreover, the learning about oneself that occurs in
various forms of psychological therapy may in itself influence the
structure and function of the brain (Kandel 1998) or may have
a significant impact on serotonin metabolism (Viinamaki 1998).
’Third wave CBT’ applies to behavioural psychological therapies
that integrate mindfulness and acceptance of unwanted thoughts
and feelings with a behavioural understanding of emotional suf-
fering, to elicit change in thinking process. Behavioural therapy
includes methods that focus on behaviours, not the thoughts and
feelings that might be causing them. The behavioural approach
to therapy assumes that behaviour that is associated with psycho-
logical problems develops through the same processes of learning
that affect the development of other behaviours. Psychodynamic
therapy focuses on unconscious processes as they are manifested in
people’s present behaviour. Hence by making the unconscious as-
pects of their life a part of their present experience, psychodynamic
therapy helps people understand how their behaviour and mood
are affected by unconscious feelings. Humanistic psychotherapy
emphasises human uniqueness, positive qualities, and individual
potential. It works by emphasising one’s capacity tomake informed
and rational choices and develop to one’s maximum potential. In-
tegrative therapies are approaches that combine components of
different psychological therapy models.
Why it is important to do this review
Anxiety disorders in people with COPD have been shown to in-
crease disability and impair functional status, resulting in an overall
reduction in their quality of life (Beck 1988;Weaver 1997). Impor-
tantly, the impact of anxiety on these outcomeswas shown after ad-
justing for other potential confounders such as general health sta-
tus, other medical conditions and COPD severity (Brenes 2003).
Kim2000 reported that anxiety and depressionweremore strongly
related to functional status than the severity of COPD. Screening
data from a large randomised controlled trial in the UK showed
anxiety was common in COPD and was not correlated with
COPD severity (Heslop-Marshall 2014). Co-morbid anxiety in
an elderly population with COPD has been suggested as a signif-
icant predictor of the frequency of hospital admissions (Yohannes
2000). A recent study has shown that among people with COPD,
anxiety is related to poorer health outcomes including worse sub-
maximal exercise performance, greater risk of self-reported func-
tional limitations and a higher longitudinal risk of COPD exac-
erbations (Eisner 2010).
The evidence for treatment of anxiety disorders in COPD is lim-
ited, and there are limited data to support the efficacy of medi-
cation-only treatments (Borson 1998). The results of a Cochrane
Review evaluating the effects of pharmacological interventions for
anxiety in people with COPD are inconclusive (Usmani 2011).
A feasibility study of antidepressants in this population suggested
poor acceptance of antidepressants for various reasons includ-
ing side-effects and reluctance to take “yet another medication”
(Yohannes 2001). Furthermore the association between anxiety/
panic and dyspnoea/COPD had been explained by various psy-
chological theories (Clark 1986; Livermore 2010b). It is impor-
tant therefore, to evaluate psychological therapies for the allevia-
tion of these symptoms in people with COPD.
In light of the health burden caused by psychological disorders
and the limited evidence supporting treatment options, this review
is one of four linked Cochrane Reviews that assess the effects of
pharmacological and psychological therapies for the treatment of
anxiety and depression in people with COPD, one of which has
already been published (Usmani 2011).
O B J E C T I V E S
To assess the effects of psychological therapies for the treatment of
anxiety disorders in people with chronic obstructive pulmonary
disease.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), including cross-over trials
and cluster-randomised trials.
Types of participants
Participants were adults over 40 years of age (as clinically signifi-
cant COPD is generally seen in people more than 40 years of age
(GOLD 2013)) of either gender and of any ethnicity, diagnosed
with COPD and a recognised anxiety disorder or anxiety symp-
tom(s).
The COPD diagnosis needed to have been made objectively, for
example, according to GOLD (Global initiative for chronic Ob-
structive LungDisease) criteria, or similar criteria (e.g. FEV1/FVC
less than 0.70).
The anxiety disorder (e.g. generalised anxiety disorder (GAD),
panic disorder (PD), agoraphobia, neurocirculatory asthenia, ob-
sessive-compulsive disorder (OCD), phobic disorders) needed be
defined either using established diagnostic criteria, for example,
DSM criteria (APA 1994) or anxiety symptoms identified using
a formal psychological instrument, for example, Beck Anxiety In-
ventory (BAI) (Beck 1961; BAI 1993) or Hospital Anxiety & De-
pression Scale (Zigmond 1983) at the time of recruitment to the
trial.
We included participants with co-morbid mental health disorders.
Anxiety did not need to be the primary mental health disorder for
included participants as long as they had formally diagnosed or
symptomatic anxiety (as diagnosed or assessed by a formal criteria
or a validated tool).
We excluded studies that only assessed psychological therapies for
the treatment of depression in people with COPD, as these will
be covered by a separate review.
Types of interventions
We included studies assessing any form of psychological therapy
for the treatment of anxiety disorders in people with COPDwhere
this was compared with either no intervention or education only.
Studies inwhich the psychological therapywas delivered in combi-
nation with another intervention (co-intervention) were included
only if there was a comparison group that received the co-inter-
vention alone.
Experimental interventions:
• Cognitive behavioural therapy (CBT) (e.g. problem
solving, rational emotive therapy)
• Third Wave CBT (i.e. acceptance and commitment therapy,
compassionate mind training, functional analytic psychotherapy,
mindfulness-based cognitive therapy, behavioural activation,
meta-cognitive therapy and dialectical behavioural therapy)
• Behavioural therapy (e.g. behaviour modification,
assertiveness training)
• Psychodynamic therapy (e.g. insight-oriented therapy,
group psychotherapy)
• Humanistic therapy (e.g. expressive therapy, supportive
therapy)
• Integrative therapy (e.g. cognitive analytical therapy)
Comparators:
• No intervention (i.e. waiting list and usual care)
• Education only (education (written or oral), such as
provision of information about physical and mental health issues
during a medical consultation or during a visit with a nurse where
no formal counselling or psychological therapy was provided)
• Co-intervention (only if the same co-intervention was used
in the intervention arm of the study). The co-interventions
considered were pharmacotherapy and pulmonary rehabilitation.
Types of outcome measures
Primary outcomes
• Change in anxiety symptoms as measured by a standardised
or validated anxiety measure, for example, State-Trait Anxiety
Inventory (STAI) (Spielberger 1970), the Hospital Anxiety and
Depression Scale (HADS) (Zigmond 1983) and the Beck
Anxiety Inventory (BAI) (Beck 1961; BAI 1993). These scales
generated a total score which were recorded for all pair-wise
comparisons as short-term follow up data (up to and including
six months) or long term follow-up data (greater than six
months), or both.
• Adverse events
Secondary outcomes
Each of the secondary outcomes were assessed based on a validated
assessment scale. The secondary outcomes measured included:
• Change in quality of life, for example, the St George’s
respiratory questionnaire (SGRQ) (Jones 1991). Generic,
validated quality-of-life measures were also considered
• Difference in exercise tolerance, for example, the six-minute
walk test (Butland 1982)
• Change in dyspnoea scores, for example, the Borg scale
(Borg 1982)
• Change in length of stay or readmission rate
• Change in forced expiratory volume in one second (FEV1)
Timing of outcome assessment
Time frames were defined as short-term (up to three months),
medium-term (three to six months) and long-term follow-up
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(more than six months). The primary time point used in the ’Sum-
mary of findings’ table is the longest reported follow-up by each
included study. The range of follow-ups for each outcome is de-
scribed in the ’Summary of findings’ table and in the Results sec-
tion of the review.
Search methods for identification of studies
Electronic searches
Cochrane Specialised Registers
Cochrane Common Mental Disorders Register (CCMDCTR)
Cochrane CommonMental Disorders maintains a specialised reg-
ister of RCTs, theCCMDCTR.This register contains over 40,000
reference records (reports of RCTs) for anxiety disorders, depres-
sion, bipolar disorder, eating disorders, self-harm and other men-
tal disorders within the scope of this Group. The CCMDCTR
is a partially studies-based register with more than 50% of refer-
ence records tagged to c. 12,500 individually PICO-coded study
records. Reports of trials for inclusion in the register are col-
lated from (weekly) generic searches of MEDLINE (1950-), Em-
base (1974-) and PsycINFO (1967-), quarterly searches of the
Cochrane Central Register of Controlled Trials (CENTRAL) in
the Cochrane Library, and review-specific searches of additional
databases. Reports of trials are also sourced from international
trials registries, drug companies, the handsearching of key jour-
nals, conference proceedings and other (non-Cochrane) system-
atic reviews and meta-analyses. Details of CCMD’s core search
strategies (used to identify RCTs) can be found on the Group’s
website with an example of the core MEDLINE search displayed
in Appendix 1.
CCMD’s Information Specialist cross-searched the CCMDCTR-
Refs and CCMDCTR-Studies registers (to 14 August 2015) using
the following terms:
(anxi* or *phobi* or PTSDor post-trauma* or posttrauma or “post
trauma*” or “combat disorder” or panic or OCD or obsess* or
compulsi* or GAD or stress* or distress* or neurosis or neuroses
or neurotic or psychoneuro*)
AND
((obstruct* and (pulmonary or lung* or airway* or airflow* or
bronch* or respirat*)) or COPD or emphysema or (chronic* and
bronchiti*))
Cochrane Airways’ Register (CAGR)
Cochrane Airways’ Specialised Register is also derived from
systematic searches of bibliographic databases including: the
Cochrane Central Register of Controlled Trials (CENTRAL; in
the Cochrane Library), MEDLINE, Embase, CINAHL, AMED,
and PsycINFO, and handsearching of respiratory journals and
meeting abstracts (details of the CAGR can be found on the
Group’s website).
Cochrane Airways’ Information Specialist searchedCAGR records
coded as ’COPD’ for ’AnxietyDisorders’ as listed above (14August
2015).
An additional search of CENTRAL andPsycINFOwas conducted
at this time, to ensure no records had been missed from these
databases in the creation of the CCMDCTR and CAGR (Spe-
cialised Registers) (Appendix 2).
Searching the CAGR, CENTRAL and PsycINFO did not retrieve
any additional studies beyond those identified by the CCMD-
CTR, so in 2015 we decided to conduct update searches on the
CCMDCTR alone.
National and international trials registers
Complementary searches were conducted on the World Health
Organization International Clinical Trials Registry Platform (
ICTRP) and ClinicalTrials.gov.
Searching other resources
We handsearched reference lists of retrieved, relevant articles to
identify any other potentially relevant articles. We contacted au-
thors of potentially-included studies for raw data or unpublished
data where required.
Data collection and analysis
Selection of studies
Two of three review authors (either KC, ZU or KHM) indepen-
dently assessed all citations generated from the search strategies
to determine whether they satisfied the Criteria for considering
studies for this review, through screening of the title, abstract and
descriptors. Two of three review authors, as above, retrieved and
independently examined the full texts of studies identified as po-
tentially relevant for final inclusion. We resolved disagreements
through discussion and by involving a third party if necessary (BS
or AD).
Data extraction and management
Two independent review authors (a combination of ZU, KC and
KHM) extracted the following data using a standardised and pi-
loted data extraction form, for each included study. The review
authors resolved any discrepancies by discussion between them-
selves and if needed, a third party (BS or AD).
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Study eligibility
Study design, population group and description of psychological
therapy.
Participants
Number of participants, age, gender distribution, ethnicity and
co-morbidities.
Interventions
Description of intervention, duration, intensity, who it was deliv-
ered by.
Main comparisons
Comparison 1: Psychological therapies versus no intervention
Comparison 2: Psychological therapies versus education
Comparison 3: Psychological therapies and co-intervention versus
co-intervention alone
We stratified these comparisons according to psychological ther-
apy, however, we did not perform an overall pooled estimate for in-
tervention effectiveness for all the psychological therapies in each
of these comparisons, that is, we used sub-totals only in the anal-
yses.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias for all
the included studies using the Cochrane tool for assessing risk of
bias, which is a domain-based evaluation (Higgins 2011a). We as-
sessed risk of bias as ’Low risk of bias’, ’High risk of bias’ and ’Un-
clear risk of bias’ as per the guidelines in the Cochrane Handbook
for Systematic Reviews of Interventions, table 8.5.c (Higgins 2011a).
We resolved any conflicts in the assessment either by consensus or
by referring to a third party. The domains we evaluated were:
Sequence generation
Methods considered adequate included: random number table,
computer random-number generator, coin toss, shuffling cards or
envelopes, throwing dice and drawing lots.
Allocation concealment
Methods considered adequate included: central allocation (phone,
web, pharmacy), sequentially-numbered identical drug containers
and serially-numbered sealed and opaque envelopes.
Blinding (of participants)
We considered blinding adequate if: trial authors mentioned that
participants were blinded to the intervention, although for psy-
chological therapies this was unlikely due to the difficulties asso-
ciated with delivery of communication-based interventions.
Blinding (of outcome assessors)
We considered blinding adequate if: authors mentioned that out-
come assessors were blinded to sequence allocation.
Incomplete outcome data
We assessed risk of bias due to incomplete outcome data on the
grounds of whether the incomplete outcome data were adequately
addressed or not, as per the Cochrane Handbook for Systematic
Reviews of Interventions section 8.12.
Selective outcome reporting
We considered studies to be at low risk of bias if a protocol was
available and all prespecified outcomes were reported in the pre-
specified way, or in the absence of a protocol, if all expected out-
comeswere reported (and as per recommendations in theCochrane
Handbook for Systematic Reviews of Interventions, table 8.5.c.
Other bias
We considered studies at a low risk of other bias if they were con-
ducted in such a way as to ensure no other influencing factors that
could potentially affect the outcome were evident. Examples of
other biases included: extreme baseline imbalances for participants
or outcomes, contamination of the intervention or control group,
and selective recruitment of study participants.
We have presented the results of the ’Risk of bias’ assessment in
a ’Risk of bias’ table and described them narratively within the
results of the review.
Measures of treatment effect
Continuous data
We summarised available data by either mean differences (MD)
or standardised mean differences (SMD) where appropriate, using
mean values and standard deviations. We consulted a statistician
for additional support where required (AE) (Deeks 2011).
Dichotomous data
Had dichotomous data been presented we would have calculated
odds ratios with 95% confidence intervals. We would have pre-
sented data as either final values (post-intervention) or as change
from baseline, if we had not been able to retrieve raw data from
the trialists (Deeks 2011).
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Unit of analysis issues
Cluster-randomised trials
Cluster-randomised controlled trials, that is, trials in which out-
comes relate to individual participants, whilst allocation to the
intervention is by hospital, clinic or practitioner, may introduce
unit of analysis errors. Using statistical methods that assume, for
example, that all participants’ chances of benefit are independent,
ignores the possible similarity between outcomes for participants
seen by the same provider. This may underestimate standard errors
and give misleadingly narrow confidence intervals, leading to the
possibility of a type 1 error (Altman 1997). For cluster-randomised
studies, we performed analyses at the level of individuals, whilst
accounting for the clustering in the data using a random-effects
model for pooled meta-analysis, as recommended in the Cochrane
Handbook for Systematic Reviews of Interventions (chapter 16.3.3)
(Higgins 2011b) (checked by a statistician (AE)). For those studies
that did not adjust for clustering, we replaced the actual sample
size with the effective sample size (ESS), calculated using a rho =
0.02 (as per Campbell 2000).
Cross-over trials
We extracted data from cross-over studies for the first phase only
(pre-cross-over), due to the potential for a significant carry-over
effect for psychological therapies.
Studies with multiple treatment groups
We considered multi-arm trials for inclusions provided that there
was an intervention arm with any of the interventions men-
tioned in the experimental group above and a control arm with
any of the comparators mentioned above. In the case of multi-
arm trials we included each pair-wise comparison separately, but
with shared intervention groups divided out approximately evenly
among the comparators. However, in cases where the intervention
groups were deemed similar enough to be pooled, we combined
the groups using appropriate formulae in the Cochrane Handbook
for Systematic Reviews of Interventions (table 7.7.a for continuous
data (Higgins 2011c) and chapter 16.5.4 for dichotomous data,
(Higgins 2011b)).
Dealing with missing data
We evaluated missing information regarding participants on an
available case-analysis basis as described in chapter 16.2.2 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011b).Had there been statistics essential for analysismissing (e.g.
group means and standard deviations (SDs) for both groups not
reported) that could not be calculated from other data, we would
have attempted to contact the study authors to obtain the data.
Any loss of participants that occurred before the baseline mea-
surements were performed would not have affected the eventual
outcome data of the study. Any losses after the baseline measure-
ments were taken may have affected trial validity. For dropouts at
the initial phase of a trial (by the end of the second week of in-
tervention/placebo administration), we did not include their data
and for these studies we used the final data from the completers
only. For participants who dropped out after the second week or
with unclear dropout time, we used the last observation carried
forward (LOCF) as presented in the publications, or had the data
been missing we would have obtained raw data. Had we been un-
successful in obtaining this raw data, we would have reported the
missing data under ’other’ sources of bias in the ’Risk of bias’ tables
and discussed the details in the text.
Assessment of heterogeneity
We expected this review to have some heterogeneity, with factors
such as baseline severity of anxiety, severity of underlying COPD
or consistency of diagnostic thresholds for COPD, or both, time
of measurement of results and varying measuring tools used to
assess outcomes contributing. We used the Chi2 (Deeks 2011)
and I2 statistics (Higgins 2003) to quantify inconsistency across
studies in combination with visual inspection of the data for dif-
ferences between studies (e.g. types of interventions, participants
etc.). Thresholds for the interpretation of the I2 statistic can be
misleading, since the importance of inconsistency depends on sev-
eral factors (Deeks 2011). These include magnitude and direction
of the effect and strength of the evidence for heterogeneity, for
example the P value from the Chi2 test, or a confidence interval
for I2. For the purpose of this review, we considered an I2 statis-
tic representing substantial or considerable heterogeneity for fur-
ther investigation through subgroup analyses to examine possible
causes, as per chapter 9.5.2 of the Cochrane Handbook for System-
atic Reviews of Interventions (Deeks 2011). The overlapping bands
for the I2 statistic are:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
Since there were fewer than 10 studies, where we identified report-
ing biases we extrapolated them within the ’other bias’ section in
the ’Risk of bias’ tables. If in future versions of this review we in-
clude more than 10 studies in any analysis, we will assess potential
reporting biases using a funnel plot. Asymmetry in the plot might
be attributed to publication bias, but may well be due to true het-
erogeneity or a poor methodological design. In case of asymmetry,
contour lines may be included corresponding to perceived mile-
stones of statistical significance (P = 0.01, 0.05, 0.1 etc.) to funnel
plots, which may help to differentiate between asymmetry due to
publication bias from that due to other factors (Sterne 2011).
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Data synthesis
We pooled the extracted data in meta-analyses using the random-
effects model to allow for expected heterogeneity (due to expected
differences in the interventions and populations). We assessed all
the included studies for inclusion in the primary analyses, and
performed a sensitivity analysis for studies which were at an un-
clear or high risk of bias for sequence generation and allocation
concealment, and for studies involving participants who had sig-
nificant co-morbidities, for example, dementia or severe heart fail-
ure. We performed separate meta-analyses for intervention sub-
groups as defined under Subgroup analysis and investigation of
heterogeneity (Deeks 2011). For trials reporting data at more than
one point in time, we extracted data from the final follow-up pe-
riod reported by trialists. We analysed data using ReviewManager
5 (RevMan 5) software (RevMan 2014).
Subgroup analysis and investigation of heterogeneity
We have prespecified subgroups to investigate this heterogene-
ity to reduce the likelihood of spurious findings, first by limiting
the number of subgroups investigated and second by preventing
knowledge of the studies’ results influencing which subgroups are
analysed (Deeks 2011). These contributing factors were identified
as relevant in our previous completed review for pharmacological
interventions for anxiety in COPD (Usmani 2011). We have de-
scribed all included studies in table and narrative form reporting
on study design, population, intervention characteristics and out-
come measures.
We performed subgroup analyses for the above-mentioned psy-
chological therapies according to:
• duration of intervention (e.g. 0 to 3 months, 3 to 6
months, > 6 months); and
• severity of anxiety symptoms (i.e. mild, moderate and
severe accepting the study authors’ definition of this).
These subgroups permit an examination into the possible causes
of heterogeneity, however their primary objective is to extrapolate
data for the purposes of forming hypotheses.
Sensitivity analysis
Had there been sufficient data we would have conducted a sensi-
tivity analysis to examine the effects of methodological decisions
taken throughout the review process, particularly in regard to the
inclusion criteria (Deeks 2011).We would have tested the validity
and robustness of the findings by removing studies based on the
following criteria:
• inadequate sequence generation;
• inadequate allocation concealment;
• significant attrition of the study population (20% or higher
attrition);
• studies on populations with significant co-morbidities;
• cluster-randomised trials;
• cross-over studies;
• studies containing data imputed by the review authors.
’Summary of findings’ table
As there were only three included studies in this review, the ’Sum-
mary of findings’ table was limited only to the data reported under
comparison 3 (psychological interventions and co-interventions
versus co-interventions alone). Follow-up periods presented in the
’Summary of findings’ table relate to the final follow-up reported
in each study for every outcome measure (range of follow-up is
specified in the ’Summary of findings’ table). We used only pub-
lished data to populate information in the ’Summary of findings’
table. We used the GRADE approach to assess the quality of evi-
dence (GRADE 2013). The source of all information used in the
table is from the publications only. The first four outcomes listed
above under Types of outcome measures are the same outcomes
used in the ’Summary of findings’ table (Schünemann 2011).
R E S U L T S
Description of studies
Results of the search
We identified a total of 675 records from searching Cochrane spe-
cialised registers and bibliographic databases (to 14th of Aug 2015)
with 579 short-listed once duplicates were removed. We retrieved
an additional 72 records from screening clinical trials registries
and identified one citation via author contact. This resulted in a
total of 647 records screened and 32 full-text articles (including
online protocols) identified as potentially eligible. From these, we
included three studies (five full-text articles) in the final qualitative
and quantitative analyses. Seven studies are awaiting classification
and two were ongoing at the time of review completion (Figure
1).
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Figure 1. Study flow diagram
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Included studies
We included three studies in this review, with the following char-
acteristics (see also Characteristics of included studies).
Design
All three studies were single-centre, parallel RCTs coming from
Brazil (de Godoy 2003), Norway (Hynninen 2010) and the USA
(Kunik 2008).
Sample sizes
Each study reported difficulties with sample size, two being unable
to meet the target recruitment number (Kunik 2008; Hynninen
2010) and the third (de Godoy 2003) not reporting a prespecified
sample size calculation. Samples sizes ranged from n = 30 in de
Godoy 2003, n = 51 in Hynninen 2010 and the largest being n =
238 in Kunik 2008.
Setting
Specific settings for psychological therapies were not described in
detail, however two studies did report group settings for interven-
tion delivery with an average of five participants in each session for
theHynninen 2010 study and up to 10 participants in each session
for the Kunik 2008 study, whilst the setting for de Godoy 2003
was unclear. Participants of the Kunik 2008 study were recruited
from a Veterans Affairs hospital, whilst the Hynninen 2010 study
used outpatients from a University hospital and de Godoy 2003
recruited from a pulmonary rehabilitation clinic.
Participants
All three studies recruited people with diagnosed COPD and anx-
iety using a validated tool. Although all studies recruited par-
ticipants from the hospital setting, two studies ( Kunik 2008;
Hynninen 2010) also used external advertisements/flyers to at-
tract participants into the study. The male to female ratio in the
Hynninen 2010 study was similar, however there were more men
recruited into both the de Godoy 2003 study (22 men and 8
women) and theKunik 2008 study (226men and 9women).Only
the Kunik 2008 study reported on participant ethnicity with 192
white, seven Hispanic and 38 black participants recruited. Of the
256 eligible participants for the Kunik 2008 study, 238 were ran-
domised but only 181 attended their first session (24% attrition
before the intervention commenced).
Interventions and comparators
de Godoy 2003 used psychotherapy in addition to exercise, phys-
iotherapy and education in comparison to exercise, physiother-
apy and education alone. Hynninen 2010 and Kunik 2008 both
employed Cognitive and Behavioural Therapy (CBT) in addition
to co-interventions of telephone counselling and group discus-
sions for each study respectively. The control population of the
Hynninen 2010 study used an enhanced standard care programme
for COPDwith regular telephone contacts whilst the Kunik 2008
control group received COPD education. Although we defined
the control of the Kunik 2008 study to be a co-intervention, it
could also have been considered as an education-only interven-
tion. However, due to the small number of included studies in this
review (three studies) we classified all studies as co-interventions,
which also facilitated meta-analysis and interpretation of results.
Outcomes
All three studies measured anxiety using the Beck Anxiety Inven-
tory (BAI). A number of secondary outcomes were also assessed
including depression, quality of life, exercise capacity and service
utilisation.
Excluded studies
We excluded 13 of the potentially eligible studies (15 full-text
articles) from the review due to no diagnosis of anxiety at baseline
(n = 7; Aubuchon 1990; Blake 1990; Gift 1992; Livermore 2010a;
Williams 2011; Doyle 2013; Blumenthal 2014), the intervention
not meeting the criteria for inclusion as defined in the protocol
(n = 3) due to being either an intervention of progressive muscle
relaxation without a psychological intervention (Lolak 2008), or
due to being a multi-component intervention (Pommer 2012;
Yang 2015), and we excluded the remaining three studies because
they were not randomised (Cully 2007), did not have a control
group (de Godoy 2005) or did not report anxiety data separately
(Lamers 2010). See Characteristics of excluded studies.
Ongoing studies
We identified seven studies as ongoing at the time of review com-
pletion. See Characteristics of ongoing studies for individual trial
details. We identified all the studies through either published pro-
tocols in manuscript format or via online clinical trials registries.
It is unclear if all inclusion/exclusion criteria as outlined in the
protocol of this review will be met for each study due to the limita-
tions in reported data. One study is reported to use mindfulness-
based cognitive therapy (Farver-Vestergaard 2014), whilst the re-
maining six studies specifically report the use of CBT.
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Studies awaiting classification
We classified two studies as ’awaiting classification’. One study
was a Chinese paper that could not be translated in time for in-
clusion in this review (Shao 2003). Fifty-four people with COPD
were randomised to a behavioural therapy with psychological and
somatic components or usual care, however, it is unclear if the
presence of baseline anxiety was an inclusion criteria or if people
with COPD were formally diagnosed as per the requirements for
inclusionwithin this review (see Characteristics of studies awaiting
classification). For the other study (Livermore 2015) there is a
question surrounding baseline anxiety scores for individual par-
ticipants to determine eligibility of subjects for this review. We
will continue to attempt to contact the study authors and, if no
response has been received by the time of the next update, this
study will be moved to the excluded category.
Risk of bias in included studies
For details of the risk of bias judgements for each study, see
Characteristics of included studies. We have presented a graphi-
cal representation of the overall risk of bias in included studies in
Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Sequence generation (selection bias)
Only one study adequately reported on method of sequence gen-
eration (Kunik 2008) using a computer program with blocks to
provide appropriately equal numbers per class of COPD. The in-
structor assigned treatment to the code initially through flipping
a coin. The two remaining studies reported randomisation as oc-
curring, however, they did not describe their methods in detail.
Allocation
Two studies sufficiently reported allocation concealment using an
external statistician to provide treatment codes to the study co-or-
dinator once sufficient numbers of participants for two classes had
been recruited (Kunik 2008) and by using numbered containers
that were identical in appearance for the two groups (Hynninen
2010). The de Godoy 2003 study did not report any details of
allocation concealment.
Blinding
Blinding of participants and personnel (performance bias)
Blinding to psychological therapies can be challenging unless an
active comparator arm, for example, education or sham interven-
tions is included. Two studies did not blind participants or person-
nel to the treatment allocation, whilst the third study (de Godoy
2003) reported that group 1 was blinded in relation to the activi-
ties of group 2 and vice versa.
Blinding of outcome assessors (detection bias)
Outcome assessor blinding was unclear in two studies and assessed
to be a low risk of bias in the Kunik 2008 study as authors re-
ported that study personnel performing assessments were blinded
to treatment condition.
Incomplete outcome data
All three studies had a low risk of bias for incomplete outcome data
as they used intention-to-treat analyses. Moreover, any missing
data were reported to be accounted for in the analyses.
Selective reporting
Selective reportingwas a low risk in two studies due to the availabil-
ity of prespecified published protocols, allowing adequate compar-
ison of prespecified outcomes and those reported in the publica-
tions. We assessed the de Godoy 2003 study as having an unclear
risk of bias due to the inability to review a prespecified protocol.
Other potential sources of bias
Had there been a sufficient number of studies to properly assess re-
porting bias, we would have assessed potential reporting biases us-
ing a funnel plot. Asymmetry in the plot may have been attributed
to publication bias, but may well be due to true heterogeneity or a
poor methodological design. In case of asymmetry, contour lines
would have been included corresponding to perceived milestones
of statistical significance (P = 0.01, 0.05, 0.1 etc.) to funnel plots,
which may have helped to differentiate between asymmetry due to
publication bias from that due to other factors (Higgins 2011a).
No additional formal testing for funnel plot asymmetry would
have been performed.
Although we defined the control of the Kunik 2008 study to be
a co-intervention, it could also have been considered as an edu-
cation-only intervention. However, due to the small number of
included studies in this review (three studies) we pooled all studies
together to facilitate meta-analysis.
Effects of interventions
See: Summary of findings for the main comparison
Psychological therapies for anxiety for people with COPD
Comparison 1: Psychological therapies versus no
intervention
There were no data for this comparison.
Comparison 2: Psychological therapies versus
education
There were no data for this comparison.
Comparison 3: Psychological therapies and co-
intervention versus co-intervention alone
Three studies including 319 participants contributed data to
this comparison. See also: Summary of findings for the main
comparison.
Primary outcomes
Change in anxiety symptoms
Psychological therapies were observed to be more effective for the
treatment of anxiety compared with co-interventions or usual care
(mean difference (MD) -4.41, 95% confidence interval (CI) -
8.28 to -0.53; participants = 319; I2 = 62%; P = 0.03; Analysis
1.1; Figure 4). However, there was substantial heterogeneity (I2
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= 62%), which limits the reliability of the findings. In the study
by de Godoy 2003 the psychotherapy group started with a BAI
score of 12.9 + 6.9, whilst the control population was 10.9 + 9.8.
Authors reported a change from baseline in the intervention arm
(P < 0.001), though no change was observed from baseline to
follow-up in the control group (9.2 + 8.6; P = 0.15).
Figure 4. Forest plot of comparison 1: Psychological therapies versus co-intervention, outcome: 1.1 Anxiety
Adverse events
No adverse events were reported for any of the included studies.
Secondary outcomes
Change in quality of life
Two studies with 289 participants reported quality of life through
use of three different tools, being SGRQ, SF36 and CRQ. Psycho-
logical interventions were observed to be more effective compared
to the control population for the combination of SGRQ and the
physical composite of SF36 (standardised mean difference (SMD)
-0.40, 95% CI -0.88 to -0.08; participants = 289; studies = 2; I
2 = 61%; P = 0.10). No evidence of any effect was observed for
SGRQ and the emotional composite of SF36 (SMD -0.30, 95%
CI -1.03 to 0.44; participants = 289; studies = 2; I2= 82%); Anal-
ysis 1.2). Of note substantial heterogeneity was observed in these
analyses. Alongside SF36, CRQ was also reported in the Kunik
2008 study with only one of the eight categories producing results
in favour of the CBT group for general health (end of treatment
eight-week score: intervention arm mean 34.14 + 28.53 and con-
trol arm mean 37.76 + 27.74; P = 0.05).
Difference in exercise tolerance
Compared with the control, there was no significant difference in
the number of steps taken as measured by the Six Minute Walk-
ing Distance (6MWD) when engaged in psychological therapies:
(MD -2.78, 95% CI -58.49 to 52.94, participants = 268; studies
= 2; I2 = 80%; Analysis 1.3). The Kunik 2008 study, which was
included in the meta-analysis, examined 6MWD at eight weeks’
(post-intervention) and again at 12 months’ follow-up with a dif-
ference in favour of the control arm at 12months (P = 0.05).How-
ever, the study authors reported that groupmeans at the beginning
of the follow-up period were not equal (P < 0.01), contributing to
the spurious finding.
Exercise capacity in the psychotherapy group of the de Godoy
2003 study improved almost twice as much from baseline as the
control population (P = 0.11). The study authors reported that
it may have been the improvement in physical functioning that
facilitated improvement in the psychological variables, rather than
the psychotherapy itself. ).
Change in dyspnoea scores
Only one study (Kunik 2008) reported dyspnoea via CRQ, with
an improvement in the CBT group over that of control at eight-
week end-of-treatment follow-up (intervention group mean 3.36
+ 1.64; control group mean 3.51 + 1.59; P = 0.02).
Change in length of stay or readmission rate
No studies provided data specifically on length of stay or hospi-
tal readmission rates. However the Kunik 2008 study did indi-
rectly examine this by tracking the number of treatment visits pre
and post study. No differences were observed for the ratio of pre
treatment to post treatment between groups for outpatient visits,
hospital admissions, mental health visits and emergency visits per
month, per participant.
Change in forced expiratory volume in one second (FEV1)
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No studies reported on FEV1. Whilst FEV1 is helpful to note the
severity ofCOPD, aswithmost interventions few if any other ther-
apies, including pharmacotherapies significantly improve FEV1
in COPD.
Subgroup analyses
We carried out subgroup analyses for duration of follow-up
due to multiple follow-up periods reported in the Kunik 2008
study (eight weeks, i.e. post treatment, and 12 months) and the
Hynninen 2010 study (seven weeks and six months). In both anx-
iety and quality-of-life outcomes, results became better (favoured
intervention more) with longer follow-up compared to immedi-
ately post treatment. In the case of anxiety, short-term (0 to 3
month follow-up) benefits were seen in favour of the intervention
arm with a MD of -3.86; 95% CI of -6.63 to -1.10 and P = 0.006
(I2 = 19%), whilst these findings were not maintained long-term
(6 to 12 months; MD -4.30 with 95% CI of -10.57 to 1.97 and
P = 0.18; I2 = 80%; Analysis 2.1). We did not note any evidence
of an effect for exercise capacity (Analysis 2.2) or quality of life
(Analysis 2.3, Analysis 2.4), even after sub group analyses.
D I S C U S S I O N
Summary of main results
Based on the small number of included studies within this review
(only three), it is difficult to draw any meaningful and reliable
conclusions. Some evidence of improvement in anxiety was ob-
served with a benefit in favour of the psychological therapy arm,
however, the presence of substantial heterogeneity and low quality
of the evidence limits the reliability of these findings. Six-minute
walking distance was analysed in two of the three included studies,
producing no evidence of any effect. As such there is insufficient
information to draw reliable conclusions about whether psycho-
logical therapies are beneficial for people with COPDwith anxiety
(see Summary of findings for the main comparison).
Of note however, sub-group analyses for duration of follow-up
for both anxiety and quality of life indicate the potential for
greater benefits in favour of the psychological intervention given
more time (in the presence of wider confidence intervals due to
small number of relevant studies). Although intervention treat-
ment lasted for similar periods of time (eight weeks and seven
weeks for the Kunik 2008 and Hynninen 2010 studies respec-
tively), participants within both studies did better at long-term
follow-up in comparison to immediately post-intervention. This
suggests that psychological interventions may take longer to work
than during the treatment phase alone.
Overall completeness and applicability of
evidence
A limitation of this review is that all three included studies re-
cruited participants with both anxiety and depression, not just
anxiety, whichmay confound the results, as presence of co-morbid
depression may have over estimated or under estimated the effect
of intervention in different participants (based on different levels
of severity of anxiety and depression), the details of which are out
of the scope of this review. Also important to note is that the ma-
jority of the participants of this review were men. From the pre-
specified outcomes identified as being important for this review,
none of the three included studies included as an outcome either
adverse events or objective markers of lung disease, such as FEV1.
Length of stay and readmission rate was also not effectively evalu-
ated in any of the three studies. Considering the small number of
included studies and limited reporting for each of the outcomes,
the overall completeness and applicability of evidence is poor. As
such, findings from this review should be interpreted with caution
and the questions posed in this review remain unanswered.
Quality of the evidence
The quality of evidence in this review overall was low, with two
of the three studies having prespecified protocols available for
comparison to methods, and outcomes reported on within the
final publications. Although all studies reported that randomisa-
tion occurred, only one provided a description of the methods
for sequence generation. Allocation concealment was adequately
reported in two studies whilst the third was unclear.
Consistency
Substantial heterogeneity was identified in all meta-analyses across
studies, suggesting the possibility of these being true differences
in the underlying treatment effect. However, as we only included
three studies, it is difficult effectively to examine consistency. As
such, the quality of results was downgraded due to inconsistency.
Indirectness
Due to the small number of included studies and broad classifica-
tion of psychological therapies, it is likely that this review contains
indirectness through varying interventions, comparators, popula-
tions and even outcomes and the use of different reporting tools.
Imprecision
Imprecision was identified particularly when examining exercise
capacity with the presence of wide confidence intervals around the
treatment effect. This is of particular concern when there are few
studieswith fewparticipants attempting to determine the results of
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a particular outcome. As such the quality of the 6MWD outcome
was downgraded due to imprecision.
Publication bias
It is difficult to determine the presence of publication bias and
systematic underestimation or overestimation of the underlying
beneficial or harmful effect due to inclusion of only three studies.
Screening of online clinical trial registries allows identification of
studies regardless of a positive or negative effect for the treatment,
which may reduce the possibility of publication bias. The iden-
tification of six ongoing studies and one awaiting classification is
reassuring, however, there is the possibility of negative studies be-
ing missed before publication of protocols became mandatory.
Potential biases in the review process
As the three studies identified for inclusion within the review were
from three different countries and different healthcare settings,
it is difficult to determine the extent to which the results can be
generalised. In particular, all three studies reported issues with
either prespecified sample sizes not being met ( Kunik 2008;
Hynninen 2010) or a small sample limiting the ability to draw
reliable conclusions from the results (de Godoy 2003, in which
there was no mention of sample size calculations). Authors in the
Hynninen 2010 trial reported that, due to the low sample size of
their study, it was possible that significant differences had not been
detected when they existed. They also reported that it may have
beenpossible to detect a difference on anxiety symptoms due to age
if a larger sample size hadbeen achieved. Low recruitment numbers
in the Kunik 2008 study was reported to be due to difficulties
often occurringwith recruitment ofVeteranAffairs’ patients due to
greater prevalence of physical andmental health problems. Authors
of the de Godoy 2003 study suggested that, due to the relatively
small sample size, the conclusions from their study should only be
considered as tentative.
An additional limitation relates to risk of bias categories deemed
to be unclear by review authors, as we did not contact individual
study authors for clarification or to obtain further information.
Agreements and disagreements with other
studies or reviews
Meta-analyses attempting to examine the impact of psychological
interventions for anxiety in people with COPD have consistently
identified a lack of methodologically rigorous evidence to support
treatment efficacy (Rose 2002; Mikkelsen 2004; Baraniak 2011),
resulting in the inability to draw reliable conclusions. A 2014
overview examining the prevalence, impact and management of
depression and anxiety in COPD also found that the quality of
evidence underpinning treatment varied considerably (Panagioti
2014). The authors found that interventions that included pul-
monary rehabilitation with or without psychological components
improved symptoms of depression and anxiety in COPD. They
considered cognitive and behavioural therapy and, though treat-
ment effects were small, they concluded that this type of ther-
apy could potentially lead to greater benefits in anxiety for peo-
ple with COPD if embedded in multi-disciplinary collaborative
frameworks. Another systematic review and meta-analysis of com-
plex interventions for depression and anxiety in COPD identi-
fied 28 studies for inclusion (Coventry 2013). Subgroup analyses
identified small but non-significant effects on self-reported anx-
iety symptoms post-treatment for cognitive and behavioural in-
terventions (SMD -0.17; 95% CI -0.35 to 0.01; 7 studies) and
relaxation (SMD -0.18; 95% CI -0.67 to 0.30; 3 studies), but
observed no evidence of any effect for self-management educa-
tion (SMD -0.00; 95% CI -0.17 to 0.16; 5 studies). This review
observed an improvement with the intervention for multi-com-
ponent exercise training, though the sample included substantial
heterogeneity (SMD -0.47; 95% CI -0.66 to -0.28; P = 0.002; 14
studies; I2 = 63.3%; Coventry 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the small number of included studies identified for inclu-
sionwithin this review (only three), it is difficult to draw anymean-
ingful and reliable conclusions. All three included studies recruited
participants with both anxiety and depression, not just anxiety
(which may confound the results) and compared psychotherapy
with co-intervention versus co-intervention alone. Some evidence
of improvement in anxiety was observed in the psychological ther-
apy arm, however, the low quality of the evidence and presence
of substantial heterogeneity limits our ability to draw any conclu-
sions from these findings.
Implications for research
There is a need for further research trials to evaluate the role of
psychotherapy for anxiety in people with chronic obstructive pul-
monary disease (COPD) using a population with anxiety symp-
toms and COPD. Given problems with sample size, participant
selection and only one type of psychotherapy in current stud-
ies, future researchers might need to consider multi-centre stud-
ies with different modalities of psychotherapy other than cogni-
tive behavioural therapy. New research should also assess adverse
events, the effect on hospital admissions, length of stay and long-
term effects on quality of life produced by psychotherapy.
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
de Godoy 2003
Methods Country: Brazil
Design: a blinded prospective RCT
Multicentre?: no
Funders of the trial: supported by the Universidade de Caxias do Sul (BPC level II grant)
Duration of trial: October 1999-May 2001
Duration of participation: 12-week programme
Participants Population description: people with COPD treated at a pulmonary rehabilitation clinic
in Brazil; participant’s COPD was stratified according to the Brazilian Society of Pul-
monology and Tisiology guidelines into 3 severity levels: mild, moderate and severe
Setting: all participants were referred from the University’s Department of Respiratory
Diseases to the Pulmonary Rehabilitation Clinic
Inclusion criteria: diagnosis of COPD (corroborated by clinical history, physical exami-
nation, spirometry, chest plain films, thoracic computer tomography or both and pulse
oximetry
Exclusion criteria: physical incapacity to perform the proposed protocol; refusal to par-
ticipate in the pulmonary rehabilitation programme; lack of adherence to the pulmonary
rehabilitation programme due to illness of more than 2 weeks’ duration
Method of participant recruitment: pulmonary rehabilitation clinic patients
Total number randomised: 30 participants
Withdrawals and exclusions: no withdrawals mentioned
Age: mean age 60.33
Sex: 22 men and 8 women
Race/ethnicity: not stated
Interventions Intervention
Number randomised to group: 14
Details of the interventions:
• 12 psychotherapy sessions including sessions of psychotherapy which addressed
the patient’s psychosocial needs and included his/her social, marital, work, health, and
interpersonal philosophy and habits; cognitive therapy and logotherapy techniques
were used during these sessions
Intervention intensity: 12-week treatment programme with 12 psychotherapy sessions
in addition to co-interventions of 24 physiotherapy sessions, 24 physical exercise sessions
and 3 educational sessions
Mode of delivery: unclear if intervention was delivered in group settings or to individuals
Co-interventions:
• 24 sessions of exercise (arm and leg exercises, aerobic condition with a treadmill,
and flexibility training
• 24 sessions of physiotherapy (diaphragmatic breathing, sputum clearance,
bending forward postures, pursed-lip breathing, postural drainage, chest percussion,
vibration, directed cough and forced expiratory technique was used)
• 3 education sessions (including compliance, coping with illness, stress
management, anatomy and physiology of the lungs, relaxation and energy-saving
28Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
de Godoy 2003 (Continued)
techniques, drug actions, side effects and technique for administration, good nutrition,
use of oxygen, environmental control, intimacy and sexuality, the doctor-patient
relationship, smoking cessation, benefits of exercise
Comparison
Comparison name: reported as ’Group 2’ in the paper
Number randomised to group: 16
Details of the interventions:
• 24 sessions of exercise (arm and leg exercises, aerobic condition with a treadmill,
and flexibility training)
• 24 sessions of physiotherapy (diaphragmatic breathing, sputum clearance,
bending forward postures, pursed-lip breathing, postural drainage, chest percussion,
vibration, directed cough and forced expiratory technique was used)
• 3 education sessions (including compliance, coping with illness, stress
management, anatomy and physiology of the lungs, relaxation and energy-saving
techniques, drug actions, side effects and technique for administration, good nutrition,
use of oxygen, environmental control, intimacy and sexuality, the doctor-patient
relationship, smoking cessation, benefits of exercise
Intervention intensity: 12-week treatment programme with 24 physiotherapy sessions,
24 physical exercise sessions and 3 educational sessions
Mode of delivery: unclear if intervention was delivered in group settings or to individuals
Outcomes Outcomes collected: BAI, BDI and 6MWD
Time points measured: baseline and post-intervention
Person collecting time point: not specified
Outcome measures validated?: yes for all three
Missing data addressed?: not reported
Notes Note: nomention of a sample size calculation ismade but authors do report the “relatively
small sample size” as a limitation of the study
Funding: Supported by the Universidade de Caxias do Sul (BPC level II grant); No
commercial party having a direct financial interest in the results of the research supporting
this article has or will confer a benefit upon the authors or upon any organization with
which the authors are associated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not specified
“patients were randomised into 2 groups”
Allocation concealment (selection bias) Unclear risk Details of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Group 1 was blinded in relation to the ac-
tivities of Group 2 and vice versa
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de Godoy 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Nomention of blinding for outcome asses-
sors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for choosing not to participate
prior to randomisation (n = 6 participants)
and attrition post recruitment (n = 3 inter-
vention participants) were reported for all
participants
Selective reporting (reporting bias) Unclear risk Insuffient information due to lack of pre-
specified study protocol
Other bias Low risk No other biases identified
Hynninen 2010
Methods Country: Norway
Design: prospective RCT
Multicentre?: no
Funders of the trial: no funding sources mentioned
Duration of trial: participants were enrolled over a period of 1.5 years; no other infor-
mation provided
Duration of participation: 8 months from baseline
Participants Population description: people with COPD who answered positively to at least 2 of the
5 anxiety and depression questions from the PRIME-MD questionnaire
Setting: participants in both groups attended the pulmonary clinic at baseline and 2 and
8 months later for spirometry, self-report measures and provision of Actigraph device for
sleep registration
Inclusion criteria: COPD diagnosis confirmed with post -bronchodilator spirometry
FEV1 < 80% predicted and ratio < 0.7, aged 40 years or over, had BAI scores > 15 and/
or BDI-II > 13, not participating in other psychological interventions e.g. pulmonary
rehabilitation, no cognitive impairment (MMSE score > 23) and no severe psychiatric
disorders as per DSMIV
Exclusion criteria: as per inclusion criteria
Method of participant recruitment: consecutive eligible patients who were interested in
participating in the study were recruited from an outpatient clinic at the Haukeland
University Hospital, Bergen, Norway or were recruited via a newspaper advertisement
Total number randomised: 51 participants
Withdrawals and exclusions: intervention arm: 2 discontinued intervention; control arm:
2 could not be contacted and 1 died
Age: intervention group: mean 59.3 years; control group: mean 62.6 years
Sex: intervention group: 11 women, 14 men; control group: 15 women, 11 men
Race/ethnicity: not reported
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Hynninen 2010 (Continued)
Interventions Intervention
Number randomised to group: 25 (23 received allocated intervention)
Details of the interventions:
• psychoeducation awareness (how COPD may affect psychological well-being,
patterns of anxiety and depression adding to the burden of lung disease)
• relaxation (using breathing techniques and postural changes for relaxation and
coping with physical symptoms)
• cognitive therapy (identifying unhelpful thoughts and explore more functional
patterns of thought)
• behavioural therapy (identify depressive, passive behaviours and replace them
with activities that are pleasant/increase mastery;
• fear-based exposure (replace avoidance with graded exposure to increase tolerance)
• sleep skills management (learn about sleep hygiene and use skills);
CBT was undertaken in the Department of Clinical psychology. The group session was
facilitated by two masters-level psychology students; The sessions were videotaped and
a specialist in clinical psychology monitored the students’ competence
Intervention intensity: 7 weekly 2-h sessions
Mode of delivery: group sessions (4-6 participants, 5 on average)
Co-interventions
• Participants were phoned 1 and 3 months after post-treatment assessments and
encouraged to maintain behavioural changes instigated in therapy
Comparison
Comparison name: Enhanced Standard care for COPD
Number randomised to group: 26 (23 received allocated intervention)
Details of the interventions:
• standard COPD care plus telephone contact every 2 weeks in the intervention
period of seven weeks;
• the same student therapists conducted the phone calls
Intervention intensity: phone calls every 2 weeks for intervention period; Calls lasted 5-
10 min
Mode of delivery: telephone
Co-interventions
• participants were phoned 1 and 3 months after post-treatment assessments and
encouraged to maintain behavioural changes instigated in therapy
Outcomes Outcomes collected: BAI, BDI, SGRQ, PSQI, Actigraphy (objective measure of sleep
efficiency) and CSQ
Time points measured: baseline, 2 and 8 months (or baseline, post treatment and six
months post treatment)
Person collecting time point: not reported
Outcome measures validated?: yes for all
Missing data addressed?: yes, ITT analysis used and authors report that missing data at
one measurement point did not prevent including the individual in the analysis
Notes Note: the target sample size identified as being necessary in the power analysis (33 in
each arm) was not reached by the end of the study period (25 in the intervention arm
and 26 in the control arm)
Funding: no mention of funding or financial support for this work
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation reported however methods
not described
Allocation concealment (selection bias) Low risk Allocation concealment was implemented
using numbered containers that were iden-
tical in appearance for the two groups
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither participants nor therapists were
blinded to the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Nomention of blinding for outcome asses-
sors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for attrition reported in partici-
pant flow chart. Missing outcome data at
one measurement point did not preclude
analysis as mixed models with random ef-
fect was used for analysis; Intention-to-
treat analysis occurred
Selective reporting (reporting bias) Low risk Prespecified protocol available and no se-
lective reporting identified
Other bias Low risk No other biases identified
Kunik 2008
Methods Country: USA
Design: prospective RCT
Multicentre?: no
Funders of the trial: grant from Department of Veterans Affairs, Veterans Health Ad-
ministration, Health Services Research and Development; Houston Centre for Quality
Care and Utilization Studies and South Central Medical Illness Research, Education and
Clinic Center, Department of Veterans Affairs
Duration of trial: 11 July 2002-30 April 2005
Duration of participation: 12 months’ follow-up from baseline
Participants Population description: people with a chronic breathing disorder (COPD) who had
moderate anxiety symptoms and/or depression and were receiving care at the Michael E
DeBakey VA Medical Centre (MEDVAMC) within the year before the study
Setting: participants were from the Michael E DeBakey VAMedical Center in Houston,
Texas, USA and community members meeting the criteria outside of the medical centre
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Kunik 2008 (Continued)
Inclusion criteria: diagnosis of COPD confirmed with spirometry (ratio < 70 and FEV1
< 70; according to ATS 1991); moderate anxiety (BAI ≥ 16) and/or depression (BDI >
14); and treatment by primary care or provider or pulmonologist
Exclusion criteria: cognitive disorder or evidence of score of 23 or less on MMSE, a
psychotic disorder and people with psychotic and non-nicotine substance use disorders
Method of participant recruitment: people on administrative database from the Michael
DeBakey Medical Center (MEDVAMC) were targeted for recruitment and screened, in
addition to other methods including flyers and advertisements
Total number randomised: 238
Withdrawals and exclusions: 69 participants dropped out following randomisation(be-
cause of the following reasons: medical 2, no time 6,transportation 6,no interest 49, no
information 46)
Age: Mean 66.3 + 10.2 years
Sex: 226 men and 9 women in total
Race/ethnicity: white n = 192, Hispanic n = 7 and black n = 38
Interventions Intervention
Number randomised to group: 118 (89 attended at least one CBT session)
Details of the interventions:
• education and awareness training focused on anxiety, depression and associated
physiological, cognitive and behavioural symptoms (session 1)
• relaxation training (session 2)
• increasing pleasurable activity and decreasing anxiety-related avoidance (session 2-
3)
• cognitive therapy - alternative thoughts, encouraging self statements and thought
stopping (session 4-5)
• problem-solving techniques (session 6)
• sleep management skills (session 7)
• skills review and maintenance of gains (session 8)
Intervention intensity: eight 1-h sessions
Mode of delivery: group CBT (up to 10 participants each session)
Co-interventions
• Group discussion
Comparison
Comparison name: COPD Education
Number randomised to group: 120 (92 received the education intervention)
Details of the interventions:
• COPD education 45 min sessions with similar frequency to CBT group;
• Topics included: breathing strategies, airways management, physiology of lung
disease, use of oxygen, avoidance of environmental irritants, nutrition, exercise,
smoking cessation and end-of-life planning
Intervention intensity: eight 45-min lectures and 15-min discussions (to control for
contact time)
Mode of delivery: group sessions
Co-interventions:
• Group discussion
Outcomes Outcomes collected: CRQ, SF36, BAI, BDI, 6MWD and service use determined by
number of hospitalisations, outpatient, mental health and emergency room visits
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Kunik 2008 (Continued)
Time points measured: 1 month, 2 months, 4 months, 8 months and 12 months
Person collecting time point: not reported
Outcome measures validated?: yes, with the exception of service use outcomes
Missing data addressed?: Yes, ITT analysis used and authors reported that missing data
at one measurement point did not prevent including the individual in the analysis
Notes Note: of 256 eligible participants, 238 were randomised but only 181 attended their
first session. Study authors reported that retention in research studies at that particular
facility could often be challenging with patients treated at Veteran Affairs facilities having
more physical and mental health problems than the average US citizen. Also, the sample
size calculation in the statistical analysis section stated that 120 participants per group
would be required yet this n-value was not met
Funding: study supported by grant No IIR 00-097 from the Department of Veterans
Affairs, Veteran Health Administration, Health Services Research and Development,
Washington DC and in part by Houston Center for Quality of Care and Utilization
Studies, Office of Research and Development; and the South Central Mental Illness
Research, Education and Clinical Center, Department of Veteran Affairs
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation list occurred via computer
program (SAS) with blocks to provide
appropriately equal numbers per class of
COPD; instructor assigned treatment to
the code initially by flip of coin
Allocation concealment (selection bias) Low risk The statistician provided randomisation
numbers and treatment codes to the study
co-ordinator when sufficient participants
for two classes had completed the baseline
assessment and consented to participate;
the instructor assigned the treatment to the
code initially by flipping a coin
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and staff performing the inter-
vention were not blinded to treatment al-
location
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study personnel performing assessments
were blinded to treatment condition
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data accounted for in regression
analyses; reasons for participants’ exclusion
(pre-enrolment) and attrition of partici-
pants post recruitment are reported in de-
tail within the subject flowchart; reasons for
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Kunik 2008 (Continued)
exclusion reported
Selective reporting (reporting bias) Low risk Pre-specified protocol available and no se-
lective reporting identified
Other bias Low risk No other biases identified
6MWD: Six Minute Walking Distance
BAI: Beck Anxiety Inventory
BDI: Beck Depression Inventory
COPD: chronic obstructive pulmonary disease
CRQ: Chronic Respiratory Questionnaire
CSQ: client satisfaction questionnaire
DSMIV: Diagnostic and Statistical Manual of Mental Disorders (4th Ed)
FEV1: forced expiratory volume in 1 second
ITT: intention-to-treat
MMSE: Mini-Mental State Examination
PRIME-MD: Primary Care Evaluation of Mental Disorders
PSQI: Pittsburgh Sleep Quality Index
RCT: randomised controlled trial
SGRQ: Saint George’s Respiratory Questionnaire
SF36: Medical Outcomes Survey Short Form 36
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aubuchon 1990 Participants not diagnosed with anxiety at baseline
Blake 1990 Participants not diagnosed with anxiety at baseline (diagnosed with stress) and not COPD-specific
Blumenthal 2014 Participants not diagnosed with anxiety at baseline
Cully 2007 Not a RCT as defined for this review
de Godoy 2005 No adequate control group: co-intervention in groups 1 and 3 was an exercise regimen, which was not a
prespecified co-intervention for this review
Doyle 2013 Participants not diagnosed with anxiety at baseline. No intervention arm
Gift 1992 Participants not diagnosed with anxiety at baseline
Lamers 2010 Anxiety data not reported separately
35Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Livermore 2010a Participants not diagnosed with anxiety at baseline and mean HADS scores are with normal range
Lolak 2008 Progressive muscle relaxation, not psychological intervention
Pommer 2012 Multi-component intervention, more than just a psychological intervention
Williams 2011 Participants not diagnosed with anxiety at baseline
Yang 2015 Multi-component intervention, more than just a psychological intervention
COPD: chronic obstructive pulmonary disease
HADS: Hospital Anxiety and Depression Scale
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Bove 2015
Methods Parallel RCT
Participants N = 66 subjects with severe COPD and associated anxiety randomised
Exclusion criteria: HADS-A (anxiety) subscale score of < 8, a psychiatric diagnosis, pulmonary cancer or involvement
in a different interventional trial
Interventions Single psycho-educative session in the participant’s home in combination with a telephone booster session; interven-
tion based on a manual, with theoretical foundation in CBT and psychoeducation
Usual care comparator
Outcomes Primary outcomes: HADS-A (anxiety) and HADS-D (depression)
Secondary outcomes: CRQ and SGRQ for quality of life and mastery of dyspnoea
Notes Part of a PhD project
Cully 2012
Methods Parallel RCT
Participants N= 320 participants with patient-reported functional limitations associated with COPD, and/or heart failure, with
clinically significant symptoms of anxiety and/or depression
Exclusion criteria: clinical factors e.g. ongoing psychotherapy, concurrent speciality mental healthcare and patient
factors e.g. cognitive, bipolar, psychotic or substance abuse disorders
Interventions Brief manualised CBT delivered by clinicians in comparison to usual care
Intervention group: 6 weekly treatment sessions and 2 brief (10-15-min) telephone booster sessions within a 4-month
time frame of the ACCESS
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Cully 2012 (Continued)
Intervention: core modules focus on increasing awareness and controlling physical and emotional symptoms and
subsequently producing skills aligning with their most pressing needs; therapists used a structured manual yet could
also tailor the intervention with the participant based on their needs; participant workbook also provided
Control group: usual care with feedback about their depression and anxiety
Outcomes Participant outcomes: depression, anxiety and physical health functioning
Implementation outcomes: participant engagement, adherence and clinician brief CBT adoption and fidelity
Notes
Farver-Vestergaard 2014
Methods Double-blind RCT
Participants Estimated n = 120 participants with severe to very severe COPD,motivated to participate in pulmonary rehabilitation
and with sufficient mobility to attend pulmonary rehabilitation
Exclusion criteria: certain co-morbidities (e.g. unstable coronary complications, psychiatric illness), severe cognitive
disability (e.g. dementia) and inability to speak Danish
Interventions Mindfulness-based cognitive therapy + pulmonary rehabilitation compared to pulmonary rehabilitation only
Intervention group: 8-week manual-based programme developed by Segal, Williams and Teasdale (2013) adjusted
to the COPD population; programme delivered as an add-on to an 8-week standardised rehabilitation programme
consisting of physical exercise and COPD-specific patient education
Control group: 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific
patient education
Outcomes Primary outcomes: quality of life (CAT), anxiety and depression (HADS), and BODE index
Secondary outcomes: physical activity (measured by accelerometry), inflammation and oxidative stress (measured by
gene expression profiling)
Notes
Heslop 2013
Methods Parallel RCT
Participants N = 312 participants with a confirmed diagnosis of COPD (FVC/FEV1 ratio < 70%, (NICE 2010); including mild-
moderate (FEV1 > 50% predicted) and severe-very severe (< 50% predicted)), probable anxiety defined by HADSA
> 8, willing to participate and provide informed consent, agreed to attend minimum of 2 and maximum of 6 CBT
sessions
Exclusion criteria: people with HADS-A scores < 8, known psychosis or personality disorders, currently receiving
psychological therapy including counselling or psychotherapy, unable to engage in CBT (due to cognitive impairment
or dementia) and limited verbal and/or written communication problems
Interventions Psychological treatment for anxiety and depression through CBT compared to self-help leaflets
Intervention group: 2-6 sessions depending on participant need and progress as per HADS (usually involved 1
session of CBT every two weeks); components of CBT included developing a CBT formulation, psychoeducation
about COPD with panic/depression, identifying/challenging negative or unhelpful thinking, identifying challenging
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Heslop 2013 (Continued)
negative or unhelpful behaviours, distraction, breathing control, relaxation, mindfulness, behavioural experiments
and graded exposure
Control group: self-help leaflets
Outcomes Primary outcome: HADS (3 months)
Secondary outcomes: HADS (6 and 12 months)
Notes
Livermore 2015
Methods RCT
Participants People with moderate to severe COPD
Interventions CBT (4 sessions) versus usual care
Outcomes Dyspnea scores
Notes We have tried to contact the study authors to get more information in regards to the baseline anxiety scores of the
individual participants to assess the eligibility of some of the participants for this review. Wewill continue intermittent
attempts at contact and if no response has been received by the time of the next update, this study will be moved to
the excluded category
Phan 2015
Methods Parallel, multi-arm RCT
Participants N = 128 people attending the COPD outpatient community clinics in Perth,Western Australia were included if they
had a diagnosis of COPD confirmed from medical records and screened positive for anxiety and depression
Exclusion criteria: life expectancy of less than 6 months, were currently involved in another research study, had an
illness exacerbation resulting in hospitalisation within the previous month, were not fluent in English, or were blind,
deaf or diagnosed with dementia or Alzheimer’s disease
Interventions Six weeks of 2 formats of CBT, being group therapy (6-16 people in each group) versus a self-paced simulation-based
learning resource (DVD) compared to usual care; group therapy consisted of 2 half-day sessions a fortnight apart and
a 1-hour telephone booster session 4 weeks later; the sessions were semi-structured in nature and included both CBT
global concepts and those that were specific to people with COPD; a manual was provided to participants for referral
to CBT concepts; CBT included information about treatment rationale explaining the link between cognitions,
behaviours and breathing, coping skills training, cognitive restructuring and the application and maintenance of
learned coping skills; The self-paced simulation included 6 vignettes (participants were asked to watch one per week)
approximately 10 min in length on CBT skills to cope with anxiety disorders and depression, a resource manual to
guide participants through the video and a weekly phone call by a researcher to check if each vignette was watched,
activities completed and if participants had any questions
Usual care group was under the usual treating physician; telephone follow-up (or home visits for those with hearing
difficulties) occurred at one week post-intervention completion, 3, 6, 9 and 12 months
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Phan 2015 (Continued)
Outcomes Primary outcomes: BAI and BDI
Secondary outcomes: SGRQ, absolute FEV1, FEV1 % predicted, FVC
Notes
Shao 2003
Methods The aim of the study was to explore the effect of behavioral intervention on the quality of life among people with
COPD during the remission period
Participants 54 people with COPD were randomly divided into intervention group and control group
Interventions The 2 groups were treated with the same clinical therapy. The intervention group was also given a behavioral
intervention that included psychological therapy with a somatic function and lifestyle intervention
Outcomes All participants were evaluatedwith the FangZhong-Jun quality-of-life scale pretreatment, before discharge, 3months
and 1 year after discharge
Notes Results: at 1 year follow-up, quality of life (measured as ’ability of daily life’ and ’status of social activity’), psychological
symptom of depression, and psychological symptom of anxiety in the intervention group (2.03 +/- 0.32, 2.29 +/- 0.
77, 2.36 +/- 0.34, 2.07 +/- 0.25) were significantly lower than those in the control group (2.29 +/- 0.30, 2.39 +/- 0.
41, 2.41 +/- 0.28, 2.16 +/- 0.51), (t = 2.801, 2.914, P < 0.01, t = 2.250, 2.340, P < 0.05)
ACCESS: Adjusting to Chronic Conditions Using Eucation, Support, and Skills
BAI: Beck Anxiety Inventory
BDI: Beck Depression Inventory
BODE: Body mass index, airflow Obstruction, Dyspnea and Exercise capacity
CAT: COPD Assessment Text
CBT: cognitive behavioural therapy
COPD: chronic obstructive pulmonary disease
CRQ: Chronic Respiratory Questionnaire
HADS-A: Hospital Anxiety and Depression Scale - Anxiety Subscale
HADS-D: Hospital Anxiety and Depression Scale - Depression Subscale
FEV1: forced expiratory volume in 1 second
FVC: forced vital capacity
RCT: randomised controlled trial
SGRQ: Saint George’s Respiratory Questionnaire
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Characteristics of ongoing studies [ordered by study ID]
ACTRN12612000254897
Trial name or title Telephone Cognitive Behavioural Therapy for the treatment of depression and anxiety associated with chronic
obstructive pulmonary disease: a pragmatic randomised controlled trial
Methods Parallel RCT
Participants N = 140 participants over 45 years of age, with a HADS score of > 8 and a PHQ-9 score > 10, with a diagnosis
of COPD, living in the community and able to speak English
Exclusion criteria: people who commenced anti-depressants and/or anxiolytics in the past 3 months or have
had a clinically significant change in this medication in the last 3 months and deafness
Interventions Telephone administered Cognitive Behavioural Therapy (CBT) plus usual care
Control population not specified
Intervention group: starts with a face-to-face 50-min session at the outpatient clinic or participant’s home
followed by 8 scheduled weekly telephone calls for up to 30 min in length
Intervention includes behavioural strategies such as behavioural activation, activity scheduling, relaxation
training, exposure hierarchies and social skills training, as well as cognitive strategies, such as cognitive re-
structuring, structured problem solving and behavioural experiments
Outcomes Primary outcomes: BAI and PHQ-9 (depression scale)
Secondary outcomes: costs of illness (including medical treatment, equipment and working hours), quality
of life (AQoL-4D), client satisfaction, COPD assessment test, General Self-Efficacy scale, Working Alliance
Inventory, acute hospitalisations, number of pulmonary rehabilitation attendances
Starting date February 2012
Contact information Colleen Doyle; +61 3 8387 2169; c.doyle@nari.unimelb.edu.au; National Ageing Research Institute 34-54
Poplar Rd Parkville Victoria 3052, Australia
Notes
ACTRN12614000915651
Trial name or title Randomised controlled trial of a brief telephone based cognitive behavioural therapy (CBT) for patients with
chronic lung disease and anxiety and/or depression undergoing pulmonary rehabilitation to evaluate the effect
on quality of life, symptoms of anxiety and depression, and exacerbation rate
Methods Parallel RCT
Participants N = 100 participants with chronic lung disease, undergoing pulmonary rehabilitation and clinical or sub-
clinical anxiety or depression defined by GAI score ≥ 4/20, and/or GDS of ≥ 4/15
Exclusion criteria: inability to provide written informed consent, known psychotic disorder, cognitive impair-
ment determined by MOCA score of < 25/30 and current enrolment in other interventional clinical trials
that would potentially interfere with this study
Interventions 6 CBT sessions administered by psychology interns compared to usual care
Intervention group: 6 CBT sessions divided into: 2 face-to-face individual sessions of 1 h each, within the
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ACTRN12614000915651 (Continued)
first 4 weeks of pulmonary rehabilitation; 4 phone sessions of 60 min each undertaken for counselling, each
session will be fortnightly within the first 2 months after the face-to-face sessions; CBT intervention will be
standardised following a manual written by the Prince Charles Hospital psychology department
Control group: usual care comprised of medical treatment and pulmonary rehabilitation
Outcomes Primary outcomes: symptoms of anxiety using GAI and depression using GDS
Secondary outcomes: 6MWD, SGRQ, Asthma Quality-of-Life Questionnaire, Asthma Control Question-
naire, primary care and hospital health service utilisation, pulmonary rehabilitation attendance and partici-
pation assessment
Starting date September 2014
Contact information A/Prof Ian Yang; +61-7-31395050; Ian.Yang@health.qld.gov.au; The Prince Charles Hospital Rode Road
Chermside, Postcode 4032 Queensland, Australia; and Dr Marsus I Pumar; +61 04 37739874; marsusi-
caro@gmail.com; The Prince Charles Hospital Rode Road Chermside, Postcode 4032 Queensland, Australia
Notes
6MWD: Six Minute Walking Distance
BAI: Beck Anxiety Inventory
CBT: cognitive behavioural therapy
COPD: chronic obstructive pulmonary disorder
GAI: Geriatric Anxiety Inventory
GDS: Geriatric Depression scale
HADS: Hospital Anxiety and Depression Scale
MOCA: Montreal Cognitive Assessment (MOCA)
PHQ-9: Patient Health Questionnaire-9
SGRQ: Saint George’s Respiratory Questionnaire
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D A T A A N D A N A L Y S E S
Comparison 1. Psychological therapies versus co-intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Anxiety 3 319 Mean Difference (IV, Random, 95% CI) -4.41 [-8.28, -0.53]
2 Quality of life 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 SGRQ and SF36 Physical
composite
2 289 Std. Mean Difference (IV, Random, 95% CI) -0.40 [-0.88, 0.08]
2.2 SGRQ and SF36
Emotional composite
2 289 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-1.03, 0.44]
3 Six minute walking distance 2 268 Mean Difference (IV, Fixed, 95% CI) -2.78 [-58.49, 52.
94]
Comparison 2. Duration of intervention sub-group analyses - psychological therapies versus co-intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Anxiety 3 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Short-term (0 to 3
months)
3 319 Mean Difference (IV, Random, 95% CI) -3.86 [-6.63, -1.10]
1.2 Long term (6 to 12
months)
2 289 Mean Difference (IV, Random, 95% CI) -4.30 [-10.57, 1.97]
2 Six minute walking distance 2 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Short-term (0 to 3
months)
2 268 Mean Difference (IV, Random, 95% CI) 29.35 [-30.13, 88.
82]
2.2 Long-term (6 to 12
months)
2 268 Mean Difference (IV, Random, 95% CI) -30.08 [-170.92,
110.77]
3 Quality of life - SGRQ and SF36
Physical composite
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Short-term (0 to 3
months)
2 289 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-0.73, 0.13]
3.2 Long-term (6 to 12
months)
2 289 Std. Mean Difference (IV, Random, 95% CI) -0.40 [-0.88, 0.08]
4 Quality of life - SGRQ and SF36
Emotional composite
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Short-term (0 to 3
months)
2 289 Std. Mean Difference (IV, Random, 95% CI) -0.17 [-0.93, 0.60]
4.2 Long-term (6 to 12
months)
2 289 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-1.03, 0.44]
42Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
Protocol prepared by Zafar A Usmani, Kristin V Carson and Karen Heslop-Marshall with feedback provided by Adrian J Easterman,
Anthony De Soyza and Brian J Smith.
Data screened and extracted by ZU, KC and HM, data entry, analysis and manuscript preparation by ZU and KC with feedback on
manuscript by AE, AD and BS.
D E C L A R A T I O N S O F I N T E R E S T
Dr Zafar Usmani has previously received a grant from Cochrane Airways for his Cochrane Review. He has not received any other
funding for his research related to the management of anxiety in people with COPD.
Kristin Carson has received travel grants from the Thoracic Society of Australia and New Zealand, Healthy Development Adelaide
(associated with The University of Adelaide) and the Young Professionals Group (associated with SA Health) to attend national and
international conferences. She has received financial support and grants from multiple organisations in the past year including the
Australian andNewZealand School ofGovernment, theNational Health andMedical Research Council, Cancer Australia, the Thoracic
Society of Australia and New Zealand and Seeley International, toward supporting several research initiatives unrelated to this particular
Cochrane Review.
Karen Heslop-Marshall has received fees for speaker meetings or consultancy work on management of anxiety and depression in COPD
from a variety of commercial companies and has received a NIHR Fellowship grant to undertake a RCT of CBT in COPD.
Dr De Soyza has received no fees nor grants that relate to anxiety and depression management in COPD. He has received fees for
speaker meetings or consultancy work on management of COPD airways disease management from a variety of commercial companies.
He has also received financial support from multiple partners in the past to attend national congresses/symposia and has also had co-
funding offers towards a multi-centre bronchiectasis grant.
Professor Brian Smith has received grant funding in the past year from the Australian and New Zealand School of Government, the
National Health and Medical Research Council, Cancer Australia, the Thoracic Society of Australia and New Zealand and Seeley
International, toward supporting several research initiatives unrelated to this particular Cochrane Review.
S O U R C E S O F S U P P O R T
Internal sources
• Respiratory Department - The Queen Elizabeth Hospital, Australia.
External sources
• No sources of support supplied
43Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not conduct sensitivity analyses due to the small number of included studies reported within each meta-analysis.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anxiety Disorders [∗therapy]; Bronchitis, Chronic [psychology]; Emphysema [psychology]; Exercise Tolerance; Psychotherapy
[∗methods]; Pulmonary Disease, Chronic Obstructive [∗psychology]; Quality of Life; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Male
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